Sanofi suspends JAK2 agent clinical trials

Reuters

PARIS, Nov 18 (Reuters) - French drugs group Sanofi said on Monday it had decide to halt all clinicaltrials and cancel plans for regulatory filings with itsinvestigational JAK2 inhibitor, fedratinib.

Following a thorough risk-benefit analysis, includingconsultation with the U.S. Food and Drug Administration (FDA),study investigators, independent expert neurologists andneuro-radiologists, Sanofi determined that the risk to patientsafety outweighed the benefit that fedratinib would bring topatients, the statement said.

View Comments (0)